Please assess the completion status of the following clinical trial:

Trial Title: Vaccination With PD-L1 Peptide Against Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically verified multiple myeloma~2. Newly treated with HDT and no signs of relapse~3. Age ≥18 years~4. Performance status ≤ 2 (ECOG-scale)~5. Expected survival \> 3 months~6. Sufficiently regenerated bone marrow function, i.e.~   1. Leucocytes ≥ 1,5 x 109~  2. Granulocytes ≥ 1,0 x 109~  3. Thrombocytes ≥ 20 x 109~7. Creatinine \< 2.5 upper normal limit, i.e. \< 300 μmol/l~8. Sufficient liver function, i.e.~   1. ALAT \< 2.5 upper normal limit, i.e. ALAT \<112 U/l~  2. Bilirubin \< 30 U/l~9. Women agreement to use contraceptive methods with a failure rate of \< 1% per year during the treatment period and for at least 120 days after the last treatment.~10. For men: agreement to use contraceptive measures and agreement to refrain from donating sperm.~Exclusion Criteria:~1. Non-secretory myeloma~2. Other malignancies in the medical history excluding squamous cell carcinoma of the skin and patients cured for another malignant disease with no sign of relapse three years after ended treatment.~3. Significant medical condition per investigators judgement e.g. severe Asthma/COPD, poorly regulated heart condition, insulin dependent diabetes mellitus.~4. Acute or chronic viral infection e.g. HIV, hepatitis or tuberculosis~5. Serious known allergies or earlier anaphylactic reactions.~6. Known sensibility towards Montanide ISA-51~7. Any active autoimmune diseases e.g. autoimmune neutropenia, thrombocytopenia or hemolytic anemia, systemic lupus erythematosus, scleroderma, myasthenia gravis, autoimmune glomerulonephritis, autoimmune adrenal deficiency, autoimmune thyroiditis etc.~8. Pregnant and breastfeeding women.~9. Fertile women not using secure contraception with a failure rate less than \< 1%~10. Patients taking immune suppressive medications incl. corticosteroids and methotrexate at the time of enrollment~11. Psychiatric disorders that per investigator judgment could influence compliance.~12. Treatment with other experimental drugs~13. Treatment with other anti-cancer drugs - except bisphosphonates and denosumab~14. Patients with active uncontrolled hypercalcemia~15. Patients who have received chemotherapy, immune therapy, radiation therapy within the last 28 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vaccination (Type: EXPERIMENTAL): Vaccine: PD-L1 peptide.

Based on this trial design, predict the completion outcome and termination type (if applicable).